Biotechnology startup ALLOX has raised $10.5 million in a seed funding round led by Asabys through its Sabadell Asabys II fund, with participation from CDTI (via SICC Innvierte) and the Institut Català de Finances. The company's drug discovery platform maps the effects of thousands of genetic mutations in parallel to identify previously unexplored regulatory and allosteric targets for small-molecule therapeutics. ALLOX will use the capital to expand its platform, build proprietary AI models from biophysical datasets, grow its internal research team, and advance multiple programs into a pipeline of proprietary drug candidates alongside prospective pharma and biotech partnerships.